INTRODUCTION: Osteoporosis is a multifactorial genetic disease which greatly increases the risk of bone fracture in elderly persons. METHODS: Four hundred and three recipients of a community health screening program were examined for the presence/absence of osteoporosis and 11 kinds of gene polymorphisms as a means of determining the relation between these gene polymorphisms and osteoporosis. The gene polymorphisms screened were: alcohol sensitivity-associated polymorphisms of alcohol dehydrogenase (ADH2) Arg47His, aldehyde dehydrogenase (ALDH2) Glu487Lys, smoking sensitivity-associated polymorphisms of glutathione S transferase (GST) M1, (GST)T1, NAD(P)H quinone oxidoreductase 1 (NQO1) C609T, inflammation-associated polymorphisms of interleukin-1beta (IL-1B)T-31C, tumor necrosis factor alpha (TNF-alpha) T-1031C, endothelial constitutive nitric oxide synthase (ecNOS) Glu298Asp, longevity-associated polymorphism of mitochondrial DNA (mtDNA) 5178 A/C, allergy-associated polymorphism of interleukin-4 (IL-4), and immunity-associated polymorphism of CD14. RESULTS: A significant association was found between the ALDH2Glu478Lys gene polymorphisms and osteoporosis. In the osteoporosis group of patients, a significant difference was noted between the Lys/Lys group and the group comprising Glu/Lys and Glu/Glu groups (namely, the genotypes including Glu alleles). In the Lys/Lys group, after age, sex, BMI, smoking history and alcohol consumption history had been adjusted for, the morbidity rate was significantly elevated [odds ratio (OR): 3.33; 95% confidence interval (95% CI): 1.28-8.71; p=0.014], and the effect was even more evident in the sub-group of women with osteoporosis (OR: 4.31; 95% CI: 1.24-14.92; p=0.021). CONCLUSIONS: The present results suggest that active prophylactic interventions such as dietary, exercise, and pharmacological therapies should be offered to non-carriers of the Glu allele (Lys/Lys).
INTRODUCTION:Osteoporosis is a multifactorial genetic disease which greatly increases the risk of bone fracture in elderly persons. METHODS: Four hundred and three recipients of a community health screening program were examined for the presence/absence of osteoporosis and 11 kinds of gene polymorphisms as a means of determining the relation between these gene polymorphisms and osteoporosis. The gene polymorphisms screened were: alcohol sensitivity-associated polymorphisms of alcohol dehydrogenase (ADH2) Arg47His, aldehyde dehydrogenase (ALDH2) Glu487Lys, smoking sensitivity-associated polymorphisms of glutathione S transferase (GST) M1, (GST)T1, NAD(P)H quinone oxidoreductase 1 (NQO1) C609T, inflammation-associated polymorphisms of interleukin-1beta (IL-1B)T-31C, tumor necrosis factor alpha (TNF-alpha) T-1031C, endothelial constitutive nitric oxide synthase (ecNOS) Glu298Asp, longevity-associated polymorphism of mitochondrial DNA (mtDNA) 5178 A/C, allergy-associated polymorphism of interleukin-4 (IL-4), and immunity-associated polymorphism of CD14. RESULTS: A significant association was found between the ALDH2Glu478Lys gene polymorphisms and osteoporosis. In the osteoporosis group of patients, a significant difference was noted between the Lys/Lys group and the group comprising Glu/Lys and Glu/Glu groups (namely, the genotypes including Glu alleles). In the Lys/Lys group, after age, sex, BMI, smoking history and alcohol consumption history had been adjusted for, the morbidity rate was significantly elevated [odds ratio (OR): 3.33; 95% confidence interval (95% CI): 1.28-8.71; p=0.014], and the effect was even more evident in the sub-group of women with osteoporosis (OR: 4.31; 95% CI: 1.24-14.92; p=0.021). CONCLUSIONS: The present results suggest that active prophylactic interventions such as dietary, exercise, and pharmacological therapies should be offered to non-carriers of the Glu allele (Lys/Lys).
Authors: M Lunt; P Masaryk; C Scheidt-Nave; J Nijs; G Poor; H Pols; J A Falch; G Hammermeister; D M Reid; L Benevolenskaya; K Weber; J Cannata; T W O'Neill; D Felsenberg; A J Silman; J Reeve Journal: Osteoporos Int Date: 2001 Impact factor: 4.507
Authors: R Fontova; C Gutiérrez; J Vendrell; M Broch; I Vendrell; I Simón; J M Fernández-Real; C Richart Journal: J Endocrinol Invest Date: 2002-09 Impact factor: 4.256
Authors: E M Colin; A G Uitterlinden; J B J Meurs; A P Bergink; M van de Klift; Y Fang; P P Arp; A Hofman; J P T M van Leeuwen; H A P Pols Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958
Authors: N A Morrison; J C Qi; A Tokita; P J Kelly; L Crofts; T V Nguyen; P N Sambrook; J A Eisman Journal: Nature Date: 1994-01-20 Impact factor: 49.962
Authors: Qing Xiong; Yan Jiao; Karen A Hasty; S Terry Canale; John M Stuart; Wesley G Beamer; Hong-Wen Deng; David Baylink; Weikuan Gu Journal: Genomics Date: 2009-01-14 Impact factor: 5.736
Authors: Qiaoli Li; Vivek M Philip; Timothy M Stearns; Jason A Bubier; Benjamin L King; Benjamin E Low; Michael V Wiles; Amir Hossein Saeidian; Beth A Sundberg; Jouni Uitto; John P Sundberg Journal: J Invest Dermatol Date: 2019-06-15 Impact factor: 8.551
Authors: Yuki Matsumura; Na Li; Hanan Alwaseem; Odelya E Pagovich; Ronald G Crystal; Matthew B Greenblatt; Katie M Stiles Journal: Hum Gene Ther Date: 2020-01-28 Impact factor: 5.695
Authors: Eric R Gross; Vanessa O Zambelli; Bryce A Small; Julio C B Ferreira; Che-Hong Chen; Daria Mochly-Rosen Journal: Annu Rev Pharmacol Toxicol Date: 2014-09-29 Impact factor: 13.820
Authors: Akiko Matsumoto; David C Thompson; Ying Chen; Kyoko Kitagawa; Vasilis Vasiliou Journal: Environ Health Prev Med Date: 2016-10-06 Impact factor: 3.674